<DOC>
	<DOCNO>NCT02989844</DOCNO>
	<brief_summary>This multi-center , phase II clinical trial prevent relapse use interleukin-15 ( IL-15 ) super-agonist complex ( ALT-803 ) maintenance allogeneic hematopoietic cell transplantation ( alloHCT ) acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>QUILT-3.035 : Relapse Prophylaxis With ALT-803 AML MDS Pts Following Allo HSCT</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Diagnosis acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) allogeneic hematopoietic stem cell transplant use reduce intensity conditioning plan perform patient prior day 100 posttransplant . 2 . Able begin study treatment day +60 day +100 transplant meet follow transplant related requirement : Sustained neutrophil ( ANC &gt; 1000/mcL ) platelet ( &gt; 30,000/mcL ) engraftment &gt; 50 % donor chimerism blood bone marrow No evidence recurrent disease recent bone marrow evaluation ( day 21 28 posttransplant acceptable ) No morphologic evidence relapse ( &lt; 5 % bone marrow blast ) Ability treat outpatient setting ( inpatient ) 3 . No sign symptom acute graft versus host disease ; however prior acute GVHD resolve control low dose steroid ( &lt; 0.3 mg/kg/day least 1 week ) may eligible . 4 . One follow donor graft source : Group 1 : sibling donor Group 2 : haploidentical donor [ posttransplant cyclophosphamide ] Group 3 : unrelated donor Group 4 : unrelated umbilical cord blood 5 . Karnofsky performance status ≥ 70 % 6 . Adequate organ function within 14 day study enrollment define : Renal : serum creatinine : ≤ 2.0 mg/dL Hepatic : SGOT SGPT &lt; 3 x upper limit institutional normal ( ULN ) 7 . Sexually active female child bear potential male partner child bear potential must agree use effective contraception therapy 4 month completion therapy . 8 . Voluntary write consent prior performance research relate procedures 1 . Pregnant breastfeed ALT803 investigational agent . Women child bear potential must negative pregnancy test screening . 2 . Class II great New York Heart Association Functional Classification criterion serious cardiac arrhythmia likely increase risk cardiac complication cytokine therapy ( e.g . ventricular tachycardia , frequent ventricular ectopy , supraventricular tachyarrhythmia require chronic therapy ) 3 . Marked baseline prolongation QT/QTc interval ( e.g . demonstration QTc interval great 500 millisecond ) 4 . Active uncontrolled bacterial , fungal , viral infection prior infection must resolve follow optimal therapy . 5 . Active autoimmune disease require immunosuppressive therapy 6 . History severe asthma currently chronic medication ( mild asthma require inhaled steroid eligible ) 7 . Received investigational agent within 14 day start study treatment ( 1st dose ALT803 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>